ロード中...
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls
Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre‐exposure prophylaxis of HIV‐1 infection. Liver disease is a major cause of morbidity and mortality in HIV‐infected individuals and can impact the pharmacokinetics (PK) of HIV medications. This phase 1 stu...
保存先:
| 出版年: | Clin Pharmacol Drug Dev |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6619238/ https://ncbi.nlm.nih.gov/pubmed/30811880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.655 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|